当前位置: X-MOL 学术Psychoneuroendocrinology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial
Psychoneuroendocrinology ( IF 3.7 ) Pub Date : 2020-06-01 , DOI: 10.1016/j.psyneuen.2020.104657
Kate R Kuhlman 1 , Michael Treanor 2 , Gabriella Imbriano 3 , Michelle G Craske 4
Affiliation  

The purpose of this study was to explore whether individual differences in glucocorticoid concentrations were associated with symptom improvement following exposure therapy for patients with social anxiety disorder. To do this, 60 participants with social anxiety disorder completed a randomized-controlled trial of exposure therapy, where participants were randomized to receive scopolamine-augmentation or placebo during their 7 exposure sessions. Scopolamine is an antimuscarinic which blocks the effects of acetylcholine and reduces autonomic arousal. During sessions 1, 4, 7, and during the post-treatment extinction assessment, participants provided up to 16 saliva samples (4 in each session). Pre-treatment, post-treatment, and at 1-month follow-up, participants completed the Liebowitz Social Anxiety Scale to monitor change in fear and avoidance symptoms. Elevated endogenous in-session cortisol during exposure sessions was associated with less symptom improvement from pre- to post-treatment and at 1-month follow-up. The association between elevated endogenous in-session cortisol and attenuated symptom change was not moderated by scopolamine treatment condition. Individuals with social anxiety disorder who have elevated neuroendocrine signaling may under-benefit from exposure therapy. This is the first study, to our knowledge, to examine whether endogenous in-session cortisol concentrations predict symptom changes following exposure therapy for the treatment of social anxiety disorder. More investigation of non-invasive and reliable biological markers that explain variability in responses to effective treatments are needed.

中文翻译:

暴露疗法期间内源性皮质醇可预测症状改善:东莨菪碱增强试验的初步结果

本研究的目的是探讨糖皮质激素浓度的个体差异是否与社交焦虑障碍患者暴露治疗后症状改善有关。为此,60 名患有社交焦虑症的参与者完成了一项暴露疗法的随机对照试验,参与者在 7 次暴露期间被随机分配接受东莨菪碱增强剂或安慰剂。东莨菪碱是一种抗毒蕈碱药,可阻断乙酰胆碱的作用并降低自主神经唤醒。在第 1、4、7 节以及治疗后消退评估期间,参与者提供了多达 16 个唾液样本(每节 4 个)。治疗前、治疗后和 1 个月的随访,参与者完成了 Liebowitz 社交焦虑量表,以监测恐惧和回避症状的变化。暴露期间内源性皮质醇升高与治疗前后和 1 个月随访时症状改善较少相关。东莨菪碱治疗条件并未缓和内源性皮质醇升高与症状减轻之间的关联。神经内分泌信号升高的社交焦虑症患者可能无法从暴露疗法中获益。据我们所知,这是第一项研究内源性皮质醇浓度是否能预测暴露疗法治疗社交焦虑症后的症状变化。
更新日期:2020-06-01
down
wechat
bug